孟鲁司特钠辅助布地奈德+特布他林治疗哮喘-慢性阻塞性肺疾病重叠综合症患者的临床疗效及安全性分析

Clinical Efficacy and Safety Analysis of Montelukast Sodium Combined with Budesonide+Terbutaline in Treatment of Asthma with Chronic Obstructive Pulmonary Disease Overlap Syndrome

目的:分析孟鲁司特钠辅助布地奈德+特布他林治疗哮喘-慢性阻塞性肺疾病重叠综合症(ACOS)的临床疗效及安全性.方法:选取2019年11月至2022年11月本院收治的84例ACOS患者作为研究对象.按照治疗方法不同将其分为观察组(n=43,采取孟鲁司特钠辅助布地奈德+特布他林治疗)和对照组(n=41,采取布地奈德+特布他林治疗).比较两组治疗效果、炎症因子水平、肺功能以及不良反应发生率.结果:观察组临床总有效率显著高于对照组,差异有统计学意义(P<0.05).治疗后,观察组C-反应蛋白(CRP)、肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6水平明显低于对照组,差异有统计学意义(P<0.05).治疗后,观察组第一秒用力呼气量(FEV1),用力肺活量(FVC)及二者比值(FEV1/FVC)均高于对照组,差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:孟鲁司特钠辅助布地奈德+特布他林治疗ACOS患者可更好的抑制患者炎性反应和改善患者肺功能,临床疗效更佳,且具有较好的安全性.

Objective:To analyze the clinical efficacy and safety of montelukast sodium combined with budesonide+terbutaline in the treatment of asthma with chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods:Eighty-four patients with ACOS admitted in our hospital from November 2019 to November 2022 were selected in this study.They were divided into observation group(n=43,treated with montelukast sodium assisted budesonide+terbutaline)and a control group(n=41,treated with budesonide+terbutaline)according to different treatment methods.The treatment efficacy,inflammatory factor levels,lung function,and adverse reactions were compared between the two groups.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group,the diference was statistically significant(P<0.05).After treatment,the level of C-reactive protein(CRP)tumor necrosis factor(TNF)-αand interleukin(IL)-6 in the observation group were significantly lower than those of the control group,the differences were statistically significant(P<0.05).After treatment,the forced expiratory volume in first second(FEV1),forced vital capacity(FVC),and FEV1/FVC values in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion:Montelukast sodium assisted budesonide+terbutaline in the treatment of ACOS can better inhibit the inflammatory response and improve lung function,the clinical efficacy is better,which has good safety.